查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1517571

真菌性角膜炎治疗市场 - 按治疗类型{医疗[药物类别、给药途径]、手术}、适应症、真菌种类、年龄组、最终用户、全球预测

Fungal Keratitis Treatment Market - By Treatment Type {Medical [Drug Class, Route of Administration], Surgical}, Indication, Fungal Species, Age Group, End-user, Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 362 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于真菌性角膜炎在全球的盛行率不断增加，2024-2032年全球真菌性角膜炎治疗市场将以6.1%的复合年增长率成长。根据 EyeWiki，真菌性角膜炎是一种日益严重的全球现象，其盛行率在全球范围内不断增加。病例增加是由多种因素造成的，包括隐形眼镜卫生不当、眼睛受伤和农业实践。随着角膜真菌感染的盛行率持续上升，对快速诊断和有效治疗措施的需求也随之增加。病例数量的不断增加增加了对创新治疗解决方案的需求，并促进了应对此临床挑战所需的研究和开发。

一个明显的趋势是越来越关注联合治疗。有鑑于真菌对传统抗真菌药物抗药性的挑战，研究人员和临床医生正在探索抗真菌药物的协同组合，以提高疗效并最大限度地降低产生抗药性的风险。透过结合多种治疗方法，如抗真菌眼药水、全身性药物治疗以及角膜胶原交联等辅助治疗，医师试图改善治疗效果并加速真菌性角膜炎的癒合。

整个真菌性角膜炎治疗产业根据治疗类型、适应症、真菌种类、年龄层、最终用户和地区进行分类。

到 2032 年，深层角膜炎部分将迅速增长，因为深层角膜炎的特征是真菌渗透到角膜更深层，如果不及时治疗，会增加视力丧失和角膜穿孔的风险。因此，有效治疗深层角膜炎需要积极的抗真菌治疗，通常与角膜移植或治疗性角膜移植等外科手术相结合。随着手术技术的进步和标靶抗真菌药物的开发，深层角膜炎患者的预后显着改善，增加了根据角膜受累的严重程度和深度量身定制的综合治疗方案的需求。

到 2032 年，由于职业暴露、隐形眼镜的使用和免疫系统减弱会增加成年人对真菌性角膜炎的易感性，成人市场将出现良好成长。此外，户外活动和农业工作等生活方式因素会增加眼睛受伤和接触真菌疾病的风险。因此，成人在寻求真菌性角膜炎治疗的患者中占很大比例，这增加了针对其独特的临床需求和风险状况而量身定制的有效治疗干预措施的需求。

到 2032 年，欧洲真菌性角膜炎治疗产业将显着成长，其特点是临床知识、研究创新和监管监督的融合。欧洲拥有强大的医疗保健基础设施和眼科研究生态系统，促进学术机构、医疗保健提供者和製药公司之间的合作，开发真菌性角膜炎的疗法。英国、德国和法国等国家处于眼科领域临床研究和治疗创新的前沿，这正在推动市场成长和新疗法的采用。此外，严格的监管标准和报销实践确保患者能够获得优质护理和创新治疗。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 眼部感染的发生率增加
      • 老年人口不断增加
      • 配戴隐形眼镜的比例不断增加
      • 增加研发活动
    • 产业陷阱与挑战
      • 与抗真菌药物相关的副作用
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 药物治疗
    • 药品类
      • 多烯
        • 纳他霉素
        • 两性霉素B
      • 唑类
        • 三唑
        • 伏立康唑
        • 氟康唑
        • 伊曲康唑
        • 泊沙康唑
        • 咪唑类
        • 益康唑
        • 咪康唑
        • 酮康唑
      • 其他药物类别
    • 给药途径
      • 专题
      • 口服
      • 可注射
  • 手术治疗

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

  • 主要趋势
  • 表浅角膜炎
  • 深层角膜炎

第 7 章：市场估计与预测：按真菌种类，2021 - 2032

  • 主要趋势
  • 镰刀菌属
  • 曲菌属
  • 念珠菌属
  • 头孢菌属
  • 其他物种

第 8 章：市场估计与预测：按年龄划分，2021 - 2032

  • 主要趋势
  • 孩子们
  • 成年人
  • 老年科

第 9 章：市场估计与预测：按最终用户分类，2021 - 2032 年

  • 主要趋势
  • 医院
  • 诊所
  • ASC
  • 其他最终用户

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Alvogen
  • Aurolab
  • Bausch Health Companies Inc.
  • Eyevance Pharmaceuticals LLC
  • Gilead Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Leadiant Biosciences, Inc.
  • Merck & Co. Inc.
  • Novo Holdings A/S (Xellia Pharmaceuticals)
  • Pfizer Inc.
简介目录
Product Code: 9024

Global Fungal Keratitis Treatment Market will grow at 6.1% CAGR during 2024-2032 due to the increasing prevalence of Keratitis Fungal globally. According to EyeWiki, fungal keratitis is a growing global phenomenon with increasing prevalence worldwide. The increase in cases is due to several factors, including improper contact lens hygiene, eye injuries, and agricultural practices. As the prevalence of corneal fungal infections continues to rise, the need for rapid diagnosis and effective treatment measures increases. The growing number of cases increases the demand for innovative treatment solutions and promotes the research and development needed to address this clinical challenge.

A visible trend is an increasing focus on combination therapy. Recognizing the challenges presented by fungal resistance to conventional antifungal drugs, researchers and clinicians are exploring synergistic combinations of antifungal agents to improve efficacy and minimize the risk of developing resistance. By combining several treatments, such as antifungal eye drops, systemic medications, and adjuvant therapy, such as corneal collagen cross-linking, doctors try to improve treatment results and speed up the healing of fungal keratitis.

The overall Fungal Keratitis Treatment industry is classified based on treatment type, indication, fungal species, age group, end user, and region.

The deep keratitis segment will grow rapidly through 2032, as deep keratitis, characterized by fungal penetration into the deeper layers of the cornea, carries an increased risk of vision loss and corneal perforation if left untreated. As such, effective treatment of deep keratitis requires aggressive antifungal therapy, often combined with surgical procedures such as corneal transplantation or therapeutic keratoplasty. With advances in surgical techniques and the development of targeted antifungal agents, the prognosis of patients with deep keratitis has improved significantly, increasing the demand for comprehensive treatment regimens tailored to the severity and depth of corneal involvement.

The adult segment will grow decently through 2032 as occupational exposure, use of contact lenses, and weakened immune systems increase the susceptibility of adults to fungal keratitis. In addition, lifestyle factors such as outdoor activities and agricultural work increase the risk of eye injuries and exposure to fungal diseases. As such, adults represent a significant proportion of patients seeking treatment for fungal keratitis, increasing the demand for effective therapeutic interventions tailored to their unique clinical needs and risk profiles.

Europe Fungal Keratitis Treatment industry will grow significantly through 2032, characterized by the convergence of clinical knowledge, research innovation, and regulatory oversight. Europe has a strong healthcare infrastructure and ophthalmic research ecosystem that fosters collaboration between academic institutions, healthcare providers, and pharmaceutical companies to develop therapies for fungal keratitis. Countries such as the United Kingdom, Germany, and France are at the forefront of clinical research and therapeutic innovation in the field of ophthalmology, which is driving market growth and the adoption of new treatments. In addition, strict regulatory standards and reimbursement practices ensure that patients have access to quality care and innovative treatments.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of eye infections
      • 3.2.1.2 Growing geriatric population
      • 3.2.1.3 Increasing prevalence of contact lens wear
      • 3.2.1.4 Increasing research and development activities
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with the antifungal medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Medical treatment
    • 5.2.1 Drug class
      • 5.2.1.1 Polyenes
        • 5.2.1.1.1 Natamycin
        • 5.2.1.1.2 Amphotericin B
      • 5.2.1.2 Azoles
        • 5.2.1.2.1 Triazole
        • 5.2.1.2.1.1 Voriconazole
        • 5.2.1.2.1.2 Fluconazole
        • 5.2.1.2.1.3 Itraconazole
        • 5.2.1.2.1.4 Posaconazole
        • 5.2.1.2.2 Imidazoles
        • 5.2.1.2.2.1 Econazole
        • 5.2.1.2.2.2 Miconazole
        • 5.2.1.2.2.3 Ketoconazole
      • 5.2.1.3 Other drug classes
    • 5.2.2 Route of administration
      • 5.2.2.1 Topical
      • 5.2.2.2 Oral
      • 5.2.2.3 Injectable
  • 5.3 Surgical treatment

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Superficial keratitis
  • 6.3 Deep keratitis

Chapter 7 Market Estimates and Forecast, By Fungal Species, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Fusarium
  • 7.3 Aspergillus
  • 7.4 Candida
  • 7.5 Cephalosporium
  • 7.6 Other species

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Children
  • 8.3 Adults
  • 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Million)

  • 9.1 Key trends
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 ASCs
  • 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Alvogen
  • 11.2 Aurolab
  • 11.3 Bausch Health Companies Inc.
  • 11.4 Eyevance Pharmaceuticals LLC
  • 11.5 Gilead Biosciences, Inc.
  • 11.6 Glenmark Pharmaceuticals Ltd.
  • 11.7 Leadiant Biosciences, Inc.
  • 11.8 Merck & Co. Inc.
  • 11.9 Novo Holdings A/S (Xellia Pharmaceuticals)
  • 11.10 Pfizer Inc.